When starting a patient on a tyrosine kinase inhibitor for chronic phase CML, which drug do you choose upfront?

Randomized clinical trials with nilotinib and dasatinib versus imatinib have shown improved rates of molecular response for the second-generation TKIs:

https://www.ncbi.nlm.nih.gov/pubmed/24311723

https://www.ncbi.nlm.nih.gov/pubmed/20525993

https://www.ncbi.nlm.nih.gov/pubmed/20525995

Improved response...

I start with nilotinib. I think it is well tolerated and that molecular responses are deeper and the chance of cure is greater.